Summary & Overview
HCPCS J0275: Alprostadil Urethral Suppository, Physician-Administered
HCPCS Level II code J0275 denotes an alprostadil urethral suppository administered under direct physician supervision in a clinical setting. This code identifies clinician-administered drug therapy for erectile dysfunction or related indications when self-administration is not applicable or allowed. Nationally, correct use of this HCPCS Level II code matters for accurate claims processing, clinical documentation, and coverage determinations tied to physician-supervised drug delivery.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of payer coverage patterns, common billing considerations for clinician-administered urethral alprostadil, and operational benchmarks where available. The publication also reviews the clinical context for using an in-clinic urethral suppository versus self-administered therapies and highlights billing nuances tied to physician supervision requirements.
This summary is intended to inform billing staff, clinicians, and policy analysts about the purpose and administrative context of HCPCS Level II code J0275, typical sites of service, and the types of payer policies and documentation practices that are relevant for accurate claims submission. Data not available in the input is noted and not inferred.
Billing Code Overview
HCPCS Level II code J0275 represents an alprostadil urethral suppository intended for administration under the direct supervision of a physician. The code is used when the drug is delivered in a clinical setting rather than self-administered by the patient.
Service type: Drug administration (in-clinic, clinician-administered medication)
Typical site of service: Outpatient clinic or physician office where medication is administered under direct physician supervision
Clinical & Coding Specifications
Clinical Context
A 68-year-old male with erectile dysfunction secondary to vasculogenic disease and history of inadequate response to oral phosphodiesterase-5 inhibitors presents to a urology clinic for intracavernosal and urethral therapy discussion. The clinician elects to administer an alprostadil urethral suppository (J0275) under direct physician supervision in the clinic because Medicare allows billing for this drug only when administered under direct physician supervision. The patient is positioned in a procedure chair; a nurse or medical assistant prepares the medication and supplies. The physician or qualified practitioner performs a brief exam, provides informed discussion about expected effects and potential adverse events (pain, urethral bleeding, hypotension), and places the urethral suppository using the provided applicator. Vital signs are monitored before and after administration. The visit is documented with the diagnosis supporting the use (for example, organic erectile dysfunction), the medication name and J0275 HCPCS code, the route (intraurethral), the supervising clinician present, time of administration, lot number and amount dispensed, and any immediate adverse reactions. Billing uses the appropriate place-of-service code for an outpatient clinic or physician office and may append clinically relevant modifiers to reflect unusual circumstances or partial administration.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
52 |